RxPG News Feed for RxPG News

Medical Research Health Special Topics World
  Home
 
   Health
 Aging
 Asian Health
 Events
 Fitness
 Food & Nutrition
 Happiness
 Men's Health
 Mental Health
 Occupational Health
 Parenting
 Public Health
 Sleep Hygiene
 Women's Health
 
   Healthcare
 Africa
 Australia
 Canada Healthcare
 China Healthcare
 India Healthcare
 New Zealand
 South Africa
 UK
 USA
 World Healthcare
 
   Latest Research
 Aging
 Alternative Medicine
 Anaethesia
 Biochemistry
 Biotechnology
 Cancer
 Cardiology
 Clinical Trials
 Cytology
 Dental
 Dermatology
 Embryology
 Endocrinology
 ENT
 Environment
 Epidemiology
 Gastroenterology
 Genetics
 Gynaecology
 Haematology
 Immunology
 Infectious Diseases
 Medicine
 Metabolism
 Microbiology
 Musculoskeletal
 Nephrology
 Neurosciences
 Obstetrics
 Ophthalmology
 Orthopedics
 Paediatrics
 Pathology
 Pharmacology
 Physiology
 Physiotherapy
 Psychiatry
 Radiology
 Rheumatology
 Sports Medicine
 Surgery
  CTVS
  Plastic Surgery
  Transplantation
 Toxicology
 Urology
 
   Medical News
 Awards & Prizes
 Epidemics
 Launch
 Opinion
 Professionals
 
   Special Topics
 Ethics
 Euthanasia
 Evolution
 Feature
 Odd Medical News
 Climate

Last Updated: Oct 11, 2012 - 10:22:56 PM
CTVS Channel

subscribe to CTVS newsletter
Latest Research : Surgery : CTVS

   EMAIL   |   PRINT
Adult Stem Cells via Endoscopic Injections Can be Used to Treat Heart Failure

Nov 21, 2005 - 12:05:00 AM , Reviewed by: Rashmi Yadav
“VesCell is also much easier to harvest because it only requires drawing a small amount of blood from the patient. It does not require a surgical procedure like bone marrow or muscle tissue.”

 
[RxPG] Two leading cardiac surgeons in adult stem cell therapy for heart disease presented the use of adult stem cells via endoscopic injection to treat heart failure patients during their talks at the International Society for Heart and Lung Transplantation Fall Education Meeting: “Synergy: Mechanical and Biological Cardiac Support - Recovery, Replacement, and Repair with Cellular Therapy.”

At the afternoon session on clinical cell therapies, Dr. Amit N. Patel, Director of Cardiac Stem Cell Therapies at The McGowan Institute for Regenerative Medicine, University of Pittsburgh Medical Center (UPMC), described the endoscopic injection procedure that is used to inject stem cells directly into the heart muscle. Dr. Kitipan V. Arom, Chief Cardiac Surgeon at Bangkok Heart Hospital, collaborated with Dr. Patel on the minimally invasive technique.

Dr. Arom followed up by presenting encouraging clinical results from a number of patients treated at Bangkok Heart Hospital using this procedure and VesCell™ from TheraVitae®. VesCell is comprised of adult stem cells called Angiogenic Cell Precursors and is harvested from a small amount of the patient’s own blood.

Dr. Patel recently received approval from the US FDA to initiate clinical trials using adult stem cells derived from bone marrow to treat heart patients at UPMC. However, in Thailand, he has observed several of the procedures performed by Dr. Arom using VesCell. Dr. Patel believes that VesCell is as safe as cells taken directly from the patient’s bone marrow – and safer than cells derived from muscle tissue.

“The results are very promising and we don’t see the complications that we see with other cell types,” said Dr. Patel.

“VesCell is also much easier to harvest because it only requires drawing a small amount of blood from the patient. It does not require a surgical procedure like bone marrow or muscle tissue,” added Dr. Arom.

In the morning sessions on pre-clinical cell therapies, Ren-Ke Li, M.D., Professor of Surgery in the Department of Cardiac Surgery at the University of Toronto, discussed positive initial results from a myocardial ischemia model in rats performed with cells from TheraVitae.

About VesCell™
VesCell™ uses a patient’s own adult stem cells to treat Heart Disease and is a viable alternative for patients who either cannot undergo or choose not to undergo standard treatments such as Coronary Artery Bypass Grafting (CABG).

VesCell™ uses adult stem cells harvested from approximately ½ pint of the patients own blood to treat several heart conditions. Once harvested, the cells are differentiated and expanded in vitro into Angiogenic Cell Precursors at TheraVitae’s Labs in Israel. They are ready for implantation in about one week.



Publication: The findings were discussed at the International Society for Heart and Lung Transplantation Fall Education Meeting: “Synergy: Mechanical and Biological Cardiac Support - Recovery, Replacement, and Repair with Cellular Therapy.”
On the web: http://www.vescell.com 

Advertise in this space for $10 per month. Contact us today.


Related CTVS News
Clopidogrel does not increase postoperative bleeding risk in patients with Acute Coronary Syndrome
AAAs are best operated at large centres - study suggests
'Off-pump' CABG appears to have no benefit on cognitive or cardiac outcomes at 5 years
Minimally invasive approach and a revolutionary device to treat thoracic aortic aneurysm
Cox-maze IV: New simpler technique for persistent Atrial Fibrillation
Nesiritide may be beneficial in the prevention of renal dysfunction after CABG
Aprotinin use during CABG associated with increased mortality rates
Mayo Clinic surgeons propose a system of quality indicators for lung surgery
Off-pump CABG is a safer option
Off-pump CABG is a safer option

Subscribe to CTVS Newsletter

Enter your email address:


 Additional information about the news article
Web Site: http://www.vescell.com

Blog: http://www.stem-cell-therapy.vescell.com

About TheraVitae
TheraVitae is a private, multinational company focused on using stem cells from the patient's own blood in order to treat a variety of disorders, especially cardiovascular diseases. The company has developed a proprietary stem cell technology called VesCell™ that is currently being used by hospitals in Thailand to treat patients with heart disease. TheraVitae is based in Bangkok, Thailand, Kiryat Weizmann, Israel, and Hong Kong.

http://www.theravitae.com

About Bangkok Heart Hospital
Bangkok Heart Hospital (BHH) – the first private heart hospital in Thailand – is a leading institution in the treatment of cardiac-related disease using adult stem cells. The hospital is currently using TheraVitae’s VesCell™ adult stem cell product to treat cardiomyopathy in no-option heart patients. Additionally, BHH has initiated a clinical trial using VesCell™ in conjunction with Coronary Artery Bypass Surgery (CABG) to treat congestive heart failure.

BHH is comprised of experienced adult & pediatric cardiologists, cardiac surgeons, cardiac anesthesiologists, cardiac rehabilitation physicians and radiologists who have trained and worked overseas in countries such as the United States, Australia and Japan. Their well-trained and experienced nurses, technicians and paramedical personnel provide 24-hour care for all cardiac conditions.

http://www.bangkokheart.com

TheraVitae Thailand
36/72 PS Tower, 21/Fl., Sukhumvit 21, Klongtoey Nua, Bangkok 10110
Phone: +662-664-4290/3
Fax: +662-664-42-89

Theravitae Israel
7 Pinhas Sapir Street P.O. Box 4049, Ness Ziona 74140, Israel
Phone: +972-8-9409170
Fax: +972-8-9409167
 Feedback
For any corrections of factual information, to contact the editors or to send any medical news or health news press releases, use feedback form

Top of Page

 
Contact us

RxPG Online

Nerve

 

    Full Text RSS

© All rights reserved by RxPG Medical Solutions Private Limited (India)